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Objectives: Prescription rates of methylphenidate (MPH) are sharply
rising in most Western countries. Although it has been reported that
MPH has abuse potential, little is known about the prevalence of
intravenous (IV) abuse of MPH. The aim of the study was to inves-
tigate the prevalence of IV MPH abuse among treatment-seeking IV
substance abusers in Iceland.
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Methods: This is a descriptive population-based study using a
semistructured interview assessing sociodemographics, substance
abuse history, and the method of administration of 108 IV substance
abusers. During 1 year, consecutively admitted adult inpatients with
substance use disorder at any detoxification center in Iceland that
reported any IV substance abuse in the past 30 days were invited to
participate. Abuse was defined as nontherapeutic use of a substance
to gain psychological or physiological effect.
Results: Prevalence of any IV MPH abuse among participants was
88% in the last 30 days (95% confidence interval [CI], 0.82-0.94)
and MPH was the most commonly abused substance (65%) and the
preferred substance (63%). Around one third (30%) reported MPH as
the first IV substance ever abused. However, among those reporting a
shorter history than 10 years of IV abuse, 42% reported MPH as the
first IV substance ever abused.
Conclusions: This first nationwide study on IV abuse of MPH shows
that it is common among treatment-seeking IV abusers in Iceland and
suggests that MPH has high abuse potential. Therefore, both the use
and possible abuse of MPH in those with high abuse potential should
be monitored, especially in countries where MPH prescriptions rates
are on the rise.
Key Words: detoxification, intravenous abuse, methylphenidate, pre-
scription drugs, stimulants
(J Addict Med 2015;9: 188–194)
P rescriptions of methylphenidate (MPH) for attention-deficit/hyperactivity disorder (ADHD) have been rising
sharply in most Western countries during the past decade
(Scheffler et al., 2007; Dalsgaard et al., 2012). This rise in
MPH use has been particularly steep in Iceland. For 2 con-
secutive years (2010-2011), Iceland had a higher per capita
prescription rates of MPH than the United States, which for
several previous years had been reported to have among the
highest prescription rate in the world per capita (Kaye & Dark,
2012; United Nations, 2012). In 2012, the consumption rate of
MPH in Iceland was 14.8 defined daily doses per 1000 inhab-
itants per day versus 7.9 in the United States (United Nations,
2013).
This increase in MPH prescribing has been explained by
the growing awareness and understanding of ADHD among
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both the public and the medical community (Castle et al.,
2007; Riggs et al., 2011; Sigurjonsson, 2011; Kaye & Dark,
2012). Because of the high MPH prescription rate in Iceland,
the Directorate of Health has restricted prescription privileges
to psychiatrists, neurologists, and pediatricians (The Icelandic
Ministry of Welfare, 2011).
Methylphenidate is a reuptake inhibitor that enhances
both the effects of noradrenalin and dopamine in the cen-
tral nervous system (Heal et al., 2009). Methylphenidate has
similar pharmacological effects as better known substances
with a high abuse potential such as cocaine and amphetamine.
Methylphenidate has been shown to have similar drug-seeking
reinforcing effects as cocaine and, therefore, concerns have
been raised about its abuse potential (Wang et al., 1997; Kollins
et al., 2001; Volkow et al., 2002; Kollins, 2003). However, the
view in some reports (Volkow et al., 2002; Kollins, 2003) has
been that MPH has less abuse potential than cocaine. This
has been attributed to a relatively slow clearance rate from the
brain and hence less likelihood of repeated administration and
abuse of MPH.
Increased availability of MPH has indeed been fol-
lowed by reports of nonintravenous abuse, particularly
in countries where consumption levels are high (United
Nations, 2012). Methylphenidate is typically abused by 2 sub-
groups. First, and more commonly reported, as a cognitive
enhancer by students who want to boost their academic perfor-
mance, and second, by abusers of other substances for recre-
ational abuse (Teter et al., 2005; Wilens et al., 2008; Bagot &
Kaminer, 2014). In a systemic review, Wilens and colleagues
showed that the base rate of MPH abuse was about 5% to
35% in college-aged individuals (Wilens et al., 2008). How-
ever, in Iceland, the base rates of oral and nasal abuse are
unknown.
Intravenous (IV) abuse of MPH has rarely been reported
although its IV abuse potential was reported as early as in 1963
(McCormick & McNeel, 1963; Lucas & Weiss, 1971). Only a
few case reports and one case series have been published on
IV MPH abuse in which it has been indicated that medical and
psychiatric complications such as depression, syncope, hal-
lucinations, and paranoia are common consequences of such
abuse (Lucas & Weiss, 1971; Wiley, 1971; Spensley & Rock-
well, 1972; Parran & Jasinky, 1991).
Clinical experience shows an ongoing trend for IV MPH
abuse in Iceland. In 2010, about 90% of all IV abusers (224
patients) who were admitted to the largest treatment center
in Iceland had abused IV MPH (Sigurjonsson, 2011). It is
imperative to record and report the IV abuse potential of com-
mon prescription medicines such as MPH. Clinicians treating
ADHD must be aware of its abuse potential and government
agencies that decide public policies be informed. The aim of
this study was to investigate the prevalence of IV abuse of
MPH among inpatients reporting any IV substance abuse that
sought detoxification treatment in Iceland. Furthermore, to in-
vestigate whether IV MPH is abused more by Icelandic IV
abusers than amphetamine, because prior reports from Iceland
have shown that amphetamine has been the most common sub-
stance of choice among Icelandic IV abusers (SAA—National
Center of Addiction Medicine, 2007).
MATERIALS AND METHODS
Study Design
A descriptive population-based cross-sectional study.
Participants and Setting
Consecutively admitted substance abusers for detoxifi-
cation treatment that had abused substances intravenously in
the past 30 days before admission were asked to participate
in the study. Participants were recruited from all 3 detoxifica-
tion centers in Iceland between March 31, 2012, and March
31, 2013. The detoxification centers were Mental Health Ser-
vices at the National University Hospital, SAA—Vogur Na-
tional Center of Addiction Medicine, and Hladgerdarkot. The
Mental Health Services at the National University Hospital
provide services for those suffering from substance abuse dis-
order and physical and mental complications and offer both
acute and elective admissions. SAA—Vogur National Center
of Addiction Medicine is the largest detoxification center in
Iceland, providing services for subjects with substance abuse
disorder who do not have symptoms of serious mental illness,
and offers both acute and elective admissions. Hladgerdarkot,
a privately run not-for-profit facility, offers only elective
admissions.
The total population of Iceland is 325.671 (Statistic Ice-
land, 2014) and the total number of regular IV abusers of any
substance in Iceland has been estimated to be between 400 and
550 (SAA—Vogur National Center of Addiction Medicine,
2010). During this 12-month period, 108 participants were
recruited, representing approximately 20% of all active IV
substance abusers in the Icelandic population.
Eligible participants were identified by employers at the
3 detoxification centers at admission through medical history
and medical records. Each potential participant received an
introduction letter about the study. Those willing to partici-
pate signed an informed consent and the interviewers were
notified and arrived at the detoxification center within 2 days.
All participants were interviewed face to face by 2 of the au-
thors (G.D.B. and H.B.) in an assessment interview that usually
lasted for half an hour. Those younger than 18 years, pregnant,
suicidal, psychotic, manic, or physically too unstable to par-
ticipate in the study were excluded. Very few patients, only 4
out of 53 (8%), of those invited to take part refused to do so at
the main research site where most of the patients (45%) were
recruited. The other 2 sites were unable to register those who
refused participation for administrative reasons.
Instrument
A semistructured interview protocol was designed and
used in the study because no current protocols are designed
specifically for MPH abuse. No other additional sources
for data collection were used. After recording sociodemo-
graphic data, participants were asked which licit and illicit
substances (alcohol, cannabis, amphetamine, cocaine, crack-
cocaine, MPH, heroin, opioids, benzodiazepam, ecstasy, hallu-
cinogenic substances, pregabalin/gabapentin) they had abused,
both IV and non-IV (oral and/or nasal) in the last 30 days
and lifetime abuse. Moreover, what was their preferred IV
Copyright © 2015 American Society of Addiction Medicine. Unauthorized reproduction of this article is prohibited.
C© 2015 American Society of Addiction Medicine 189
Bjarnadottir et al. J Addict Med r Volume 9, Number 3, May/June 2015
substance and which substance they had most commonly
abused during the past 1 month, what was the first IV sub-
stance they had ever abused, their age at first injection, pre-
vious substance abuse treatments, risk-seeking behavior, total
length of abstinence, and whether they had ever been convicted
of crimes or been sentenced to prison. Sociodemographics was
defined on the basis of their highest level of education, type of
housing, type of income, and employment status. Duration of
abstinence was defined as the cumulative time of abstinence
of any substance abuse except tobacco. Risk-seeking behavior
included sharing needles, unprotected sex, and prostitution.
Age of substance abuse onset was defined as the age when
the participants stated that their substance abuse had become
problematic for any substance except tobacco. Abuse was de-
fined according to The Analgesic, Anesthetic, and Addiction
Clinical Trials, Translation, Innovations, Opportunities, and
Networks (ACTTION) recommendation: “Involves any inten-
tional, nontherapeutic abuse of a drug product or substance,
even once, for the purpose of achieving a desirable psycholog-
ical or physiological effect” (Smith et al., 2013).
A question on which IV substance was first abused was
added to the questionnaire after the study had commenced
(n = 98). Only those participants who had abused IV MPH
during the past 30 days answered the question why they had
chosen IV MPH rather than other IV stimulants (n = 95).
Statistics
All data were coded, stored, and analyzed using SPSS
11 (PC; SPSS Inc., Chicago, Illinois). When comparing 2
continuous variables, a Student t test was used. Fisher exact
test (2-tailed) was used to check for nonrandom associations
for categorical variables in contingency tables. In all calcula-
tions, a 2-tailed P value < 0.05 was considered statistically
significant.
Because the sample size is modest, the variables are more
likely to follow an uneven distribution and standard deviations
for some variables are close to the mean. Outliers were consid-
ered an important part of the sample and were not excluded.
Both medians and means are therefore presented.
Missing Values
Missing values for participants who could not or were
not able to answer some of the questions represented only
0.35% of all answers.
Ethics
The study was approved by the Icelandic Bioethics Com-
mittee (VSNb2012020009/03.15) and reported to the Icelandic
Data Protection Authority (2012020272HGK/–). The informa-
tion disclosed during the interview was confidential and did
not affect current or future treatments and was not entered into
the medical records. The participants could omit any question
and withdraw at any time but no one did.
RESULTS
A total of 108 inpatients were interviewed, mean age was
33 years, and the majority were men (63%). As a group, the
participants had a low educational attainment and a poor work
attendance record, resulting in a high proportion receiving
social benefits. The sociodemographic features of the sample
are presented in Table 1. The sociodemographics did not differ
significantly between treatment centers.
The vast majority of the 108 participants, 95 (88%; 95%
confidence interval [CI], 0.82-0.94), reported having abused
IV MPH in the past 30 days. There were no significant differ-
ences observed between males and females (P = 0.25). Am-
phetamine IV abuse was reported by 70% in the past 30 days
and was significantly less common than IV MPH abuse (88%)
in the same period (P = 0.004). No significant differences
were observed in the prevalence of MPH IV abuse between
the main research site, Landspitali University Hospital, and
the other 2 detoxification centers (P = 0.77). All substances
abused and route of administration among participants are
shown in Figure 1. One participant reported abusing heroin
exclusively IV, whereas all others who reported IV abuse also
reported using a non-IV route.
The mean age at the onset of substance abuse was 16 ±
4.5 years (median = 15 years, range 6-36 years). Mean age
of first substance injection was 22.5 ± 7.3 years (median =
20 years, range 13-59 years). Most participants in the study
TABLE 1. Summary Data of Sociodemographics and Risk-
Seeking Behavior of 108 Treatment-Seeking Patients Report-
ing Intravenous Substance Abuse in the Past 30 Days Before
Inpatient Detoxification*
Characteristics [mean (±SD)] or % (n)
Age [33 (10.2)]
Male 58 (63)
Marital status
Single/separated/divorced 76 (82)
Married/cohabiting 24 (26)
Offsprings 63 (68)
Education
Finished primary school† 57 (61)
Did not finish primary school 23 (25)
Higher education than primary school 20 (20)
Housing
Homeless 34 (37)
Own or rent an apartment 25 (27)
Staying with a family member 20 (22)
Council apartment 18 (19)
Halfway house 2 (2)
Other 1 (1)
Social status
Social welfare benefits 82 (89)
Unemployment benefits 9 (10)
No benefits 8 (9)
Employment
Disabled 53 (57)
Unemployed 35 (38)
Full- or part-time employment 11 (12)
Risk-seeking behavior
Unprotected sex during the past 30 days 66 (70)
Shared needles during the past 30 days 29 (31)
Prostitution during the past 30 days 3 (3)
Other
Convictions 65 (70)
More than 10 detoxification treatments 63 (68)
Imprisonments 38 (41)
*No significant differences were observed between treatment centers. Data are pre-
sented as % (n) or mean ± standard deviation (SD) as appropriate.
†Primary school is obligatory in Iceland from age 6 to 16 years. Council apartment:
Housing provided by local social services.
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FIGURE 1. Substances abused IV and non-IV 30 days before admission of 108 participants. AMP indicates amphetamine; BZD,
benzodiazepines; IV, intravenous; MPH, methylphenidate. One participant had abused only IV heroin and is included in the IV +
non-IV group.
had gone through many years of substance abuse with frequent
inpatient detoxification treatments and a relatively short total
duration of abstinence (Table 2).
Altogether 99 (92%; 95% CI, 0.86-0.96) participants
also reported having abused MPH non-IV in the past 30 days.
In total, 85% and 68% of the sample reported non-IV abuse of
amphetamine and prescription opioids, respectively.
When participants were asked which IV substance they
preferred and which substance they had abused most com-
monly during the past 30 days, MPH was both reported most
frequently as the preferred IV substance (63%) and most com-
monly abused (65%, Fig. 2). Of those who reported MPH to be
the most commonly substance abused (n = 70), 91% reported
that MPH was also their preferred substance. Furthermore, it
was the most frequently abused and preferred substance for
both males (62% and 59%, respectively) and females (69%
and 69%, respectively).
TABLE 2. Self-Reported Substance Abuse History of 108
Participants
Variable Mean ± SD Median (Range)
Age of substance abuse onset, y* 15.9 ± 4.5 15.0 (6.0-36.0)
Age of first IV substance abuse, y 22.5 ± 7.3 20.0 (13.0-59.0)
Duration of IV substance abuse, y 10.4 ± 9.5 7.0 (0.0-38.0)
Duration of MPH abuse, mo 56.6 ± 59.8 36.0 (0.0-276.0)
*Duration of abstinence was defined as the cumulative time of abstinence of any
substance abuse except tobacco. Age of substance abuse onset was defined as age when
the patient experienced substance abuse becoming problematic of any substance except
tobacco.
†Duration of MPH abuse was defined as abusing MPH either non-IV or IV
IV, intravenous.
The vast majority of participants had abused many sub-
stances during their lifetime. All those who reported IV abuse
also reported some non-IV administration. Almost all partici-
pants (96%) had abused IV MPH, but additionally 3% reported
non-IV abuse of MPH. Intravenous amphetamine abuse was
reported by 94% and non-IV abuse by 5%. Furthermore, IV
cocaine and opioids were abused roughly by 4 out of 5 partic-
ipants (85% and 81%, respectively) and 14% of participants
had abused those substances only non-IV during their lifetime.
Intravenous abuse of ecstasy was reported by 70% and non-IV
abuse by 26% of participants.
For most participants, stimulants were by far the most
commonly reported first ever IV substance abused (n = 98,
85%), amphetamine (40%), followed by MPH (30%), cocaine
(13%), and ecstasy (2%). Altogether 16 participants (15%)
reported abusing only IV MPH. The proportion of individuals
who reported MPH as their first IV substance was similar
among polysubstance IV abusers and those using only MPH
IV (P = 1.00).
As shown in Figure 3, the majority of the participants
reported a preference for MPH compared with other IV stim-
ulants. Participants were asked to detail their reasons for this
preference. Knowing for certain what substance they were
abusing (77%), a better intoxication effect (72%) and knowing
the exact dose of abuse (72%) were the 3 main reasons for
preferring MPH over other IV stimulants. Some 38% of the
sample reported MPH to be more readily available, 22% said
that MPH was cheaper and 12% reported that MPH had fewer
side effects than other IV stimulants.
Participants who reported MPH as their first IV
substance abused had a significantly shorter duration of
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MPH = Methylphenidate, AMP = Amphetamine, MethAMP = Methamphetamine.  
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FIGURE 2. Substances that 108 participants cited as their most commonly abused and preferred IV substance during the past
30 days. AMP indicates amphetamine; MethAMP, methamphetamine; MPH, methylphenidate.
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FIGURE 3. Reasons why IV abusers prefer IV MPH rather than
other IV stimulants (n = 95). Only participants who had abused
IV MPH in the last 30 days answered this question. Missing
values range from 3% to 7%.
IV substance abuse than those who reported other substances
as their first IV substance (mean = 4.2 and 13.4 years, re-
spectively; t = 6.3; n = 92; 95% CI, 6.26-12.03, P < 0.001).
Four in 10 (42%) of those participants with a lifetime duration
of IV substance abuse of 10 years or less reported MPH as
their first IV substance abused as opposed to 30% in the whole
sample. The vast majority, 60 (91%), most often purchased
MPH illicitly, whereas 11 (17%) had received MPH prescrip-
tions from health care professionals and 3 (5%) had purchased
MPH abroad.
DISCUSSION
This is the first nationwide cross-sectional study that
reports extensive IV abuse of MPH. The 108 participants had
a low educational level and a limited work attendance similar
to what has been reported in other IV substance abuse studies
(Vlahov et al., 2004). In total, 88% of the participants reported
having abused IV MPH at least once in the past 30 days before
admission, and an even higher proportion, 92%, had abused
non-IV MPH during the past 30 days. Methylphenidate was by
far the most frequently abused substance, both IV and non-IV
(Fig. 1). Furthermore, 63% reported that MPH was their IV
substance of choice (Fig. 2).
Changes in IV substance abuse in Iceland
In Iceland, only 2 drugs are approved for the treatment
of ADHD, MPH, and atomoxetine. A growing number of clin-
ical cases of MPH abuse receiving detoxification in Iceland
over the past decade indicate that MPH abuse has become
relatively common in Iceland. The MPH abuse has gained
increasing attention in the medical community and the me-
dia in the wake of rapidly increasing MPH prescriptions in
recent years (Zoe¨ga et al., 2009, 2011; Halldorsson, 2010).
Traditionally, amphetamine had been the substance of choice
among Icelandic IV abusers and it was frequently the first
IV substance abused in the past according to annual reports
(SAA—Vogur National Center of Addiction Medicine, 2007).
However, in recent years there has been a steady shift toward
IV abuse of MPH (SAA—Vogur National Center of Addiction
Medicine, 2010).
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In this study, overall 30% reported MPH as the first IV
substance ever abused but among those who had commenced
IV abuse within the past decade, 42% reported MPH as the first
IV substance ever abused. Therefore, MPH was the most com-
monly reported first IV substance abused among those who
were younger and had shorter duration of IV substance abuse.
It is alarming that a prescription medicine commonly pre-
scribed to children and adolescents but increasingly to adults
has become the predominant substance of choice for new IV
substance abusers in Iceland.
It is not clear why IV MPH abuse has become so common
in Iceland. Such outbreaks of abuse of prescription substances
have been reported in other countries and are by no means
limited to Iceland. For instance, IV abuse of temazepam be-
came problematic in the United Kingdom during the late 1980s
(Strang et al., 1992). Furthermore, there is some evidence that
the antipsychotic drug quetiapine may have an abuse poten-
tial (Klein-Schwartz et al., 2014). Another explanation could
possibly be the increased awareness of ADHD as a disabling
mental disorder in recent years and the relatively good ac-
cess to psychiatrists in Iceland (Economics Co-operation &
Development, 2011).
As far as we know, MPH IV abuse has not yet surfaced as
a major public health concern in other countries. This begs the
question whether the drug scene in Iceland is in some respect
unique or different from neighboring countries or whether this
development arose simply because of the high prevalence of
prescription and the increasing availability of MPH. If the lat-
ter is true, IV MPH abuse is also likely to become endemic in
many other countries where prescriptions of MPH have been
steadily increasing. Several facts argue against such explana-
tions of MPH IV abuse in Iceland. First, with the exception of
heroin, there is no scarcity of illegal drugs in Iceland, yet most
of the study participants prefer MPH over other IV substances
of abuse. The majority of participants also report that access
to MPH is not better than that to other stimulants. Second,
capital controls after the financial crisis in 2008 did not seem
to push consumption suddenly toward prescription substances,
because alarming signs of MPH abuse had already appeared
several years before the crisis. Interestingly, there are no in-
dications that the abuse of other prescription drugs, such as
opioids, has been on the rise in Iceland between 2007 and
2012 (The Icelandic Directorate of Health, 2013). Third, only
a minority of abusers reported that MPH is cheaper than other
stimulants. The street prices of cannabis and amphetamine
have remained relatively stable, whereas the price of MPH has,
in fact, increased severalfold during the last 10 years, which
is hard to explain in any other way than as a result of high
demand for the substance (SAA—Vogur National Center of
Addiction Medicine, 2013). Fourth, The Directorate of Health
and the Ministry of Welfare in Iceland have recently increased
surveillance and tightened regulations for MPH prescriptions
to prevent the highly prevalent misuse and abuse of MPH but
with limited results so far (The Icelandic Ministry of Wel-
fare, 2011). For instance, only certain specialists can initiate
MPH treatment (psychiatrists, child and adolescent psychia-
trists, neurologists, and pediatricians). Furthermore, the Ice-
landic electronic prescription monitoring database has been
made accessible for doctors by The Directorate of Health to
enable doctors to monitor possible misuse and/or abuse. Last,
and probably most importantly, the IV abusers report MPH as
their preferred IV substance and the most commonly abused
substance as well.
Study Limitations
The study sample consists of a heterogeneous group
where some participants had had a long history of IV abuse,
whereas others had relatively short periods of such abuse.
Hence the data have uneven distribution and standard devi-
ations for some variables (Table 2) are close to the mean.
Furthermore, the exact number of IV abusers in Iceland is
not known, but the estimated number is between 400 and 550
(SAA—Vogur National Center of Addiction Medicine, 2010).
We managed to recruit up to one fifth of these but admittedly
we have no means of knowing if and how treatment-seeking
IV abusers may differ from those who are more reluctant to
seek treatment with regard to IV abuse of MPH.
Study Strengths
This is a nationwide population-based study. Data col-
lection took place at all detoxification centers in Iceland,
thereby reducing the risk of referral and selection bias. Only 2
members of the study group gathered the data, thereby increas-
ing uniformity of data collection. In Iceland, there is minimal
gate keeping into detoxification treatment in all 3 inpatient
centers for detoxification. These 3 facilities where all partici-
pants were recruited therefore provide an ideal setting to col-
lect information from treatment-seeking IV abusers, a group
generally difficult to recruit for research.
CONCLUSIONS
This study confirms that MPH has IV abuse potential
and shows that MPH has become the most commonly abused
IV substance in Iceland. This has happened in the wake of
rapidly rising prescriptions over the past decade because of
increasing demand for pharmaceutical treatment of ADHD.
The results have grave implications, not only for Iceland, but
also for other countries because this problem may possibly
appear in countries where MPH prescriptions are on the rise
and have become much more prevalent than before. Vigilance
and close monitoring of the use and abuse of MPH are strongly
recommended in our view.
Future Research
It is important to further verify and characterize the pat-
tern of IV MPH abuse in Iceland and elsewhere. More research
is needed, for instance, on whether some available forms of
MPH formulations are more commonly abused or preferred
to others by IV substance abusers. Future studies should also
identify the effects of IV MPH abuse on morbidity and mor-
tality. Finally, it is important to investigate the various intoxi-
cation parameters of different MPH formulations.
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